The Endocannabinoid System Modulates Opiate Withdrawal Through Different Brain Circuits

A review of animal studies found the endocannabinoid system regulates both the physical and emotional aspects of opiate withdrawal, but through distinct brain regions, with CB1 receptor activation and blockade having different effects depending on the brain area.

Wills, Kiri L et al.·Frontiers in pharmacology·2016·Moderate EvidenceReview
RTHC-01308ReviewModerate Evidence2016RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

This review synthesized animal research on how manipulating the endocannabinoid system affects opiate withdrawal. The key insight was a dissociation between somatic (physical) and affective (emotional) withdrawal.

Somatic withdrawal symptoms (diarrhea, tremor, wet dog shakes) and affective withdrawal (aversion, anxiety, dysphoria) are mediated by different brain regions. The endocannabinoid system modulates both, but differently depending on where in the brain CB1 receptors are activated or blocked.

CB1 agonists can alleviate some somatic withdrawal symptoms. CB1 antagonists can precipitate withdrawal in dependent animals. But the effects are brain region-specific: what helps in one area may not help in another.

The review also discussed how these findings relate to the conditioned place aversion paradigm, which measures the emotional/motivational aspects of withdrawal that are thought to drive continued drug use.

Key Numbers

The review covered studies using CB1 agonists (WIN55,212-2, THC), CB1 antagonists (SR141716A/rimonabant), FAAH inhibitors, and endocannabinoid system modulators. Brain regions discussed include the basolateral amygdala, central amygdala, bed nucleus of the stria terminalis, ventral tegmental area, and periaqueductal gray.

How They Did This

Review of preclinical animal literature examining the effects of pharmacological modulation of the endocannabinoid system on opiate withdrawal. Covered both acutely and chronically dependent animal models, somatic and affective withdrawal measures, and brain region-specific manipulations.

Why This Research Matters

Opiate withdrawal is a major driver of continued opioid use and relapse. If the endocannabinoid system can modulate withdrawal, cannabis or cannabinoid-based treatments could potentially help people detox from opioids. But the brain region-specific effects mean that simple "cannabis for withdrawal" approaches may be too simplistic.

The Bigger Picture

The opioid crisis has driven interest in cannabinoid-based approaches to opioid withdrawal management. This review provides the mechanistic foundation: the endocannabinoid system does modulate withdrawal, but the effects are complex and depend on which brain circuits are engaged. This complexity explains why cannabis may help some aspects of opioid withdrawal while not addressing others.

What This Study Doesn't Tell Us

Entirely based on animal studies. The pharmacological manipulations used (direct brain infusions, systemic CB1 agonists/antagonists) do not precisely replicate how humans use cannabis. Species differences in endocannabinoid systems may affect translation. The review focuses on acute withdrawal, not the long-term aspects of opioid recovery.

Questions This Raises

  • ?Would cannabis or CBD help with the emotional aspects of opioid withdrawal specifically?
  • ?Could region-specific endocannabinoid modulation be achieved with drug design?
  • ?Do the somatic and affective withdrawal circuits respond differently to whole-plant cannabis versus isolated cannabinoids?

Trust & Context

Key Stat:
CB1 receptor effects on opiate withdrawal are brain region-specific, affecting somatic and affective withdrawal through different circuits.
Evidence Grade:
Moderate evidence from a comprehensive review of preclinical animal studies, providing mechanistic insights that await human translation.
Study Age:
Published in 2016. Interest in cannabinoids for opioid withdrawal management has grown substantially since this review.
Original Title:
Effect of Pharmacological Modulation of the Endocannabinoid System on Opiate Withdrawal: A Review of the Preclinical Animal Literature.
Published In:
Frontiers in pharmacology, 7, 187 (2016)
Database ID:
RTHC-01308

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Can cannabis help with opioid withdrawal?

Animal studies show the endocannabinoid system modulates opiate withdrawal, but the effects are complex and depend on which brain region is affected. Cannabis may help with some aspects (potentially the emotional/motivational symptoms) while not addressing others.

How do the cannabinoid and opioid systems interact?

They share overlapping brain circuits and both regulate pain, reward, and emotional states. CB1 receptor activation can alleviate some somatic withdrawal symptoms in animals, while blocking CB1 receptors can worsen withdrawal. The interaction is brain region-specific.

Read More on RethinkTHC

Cite This Study

RTHC-01308·https://rethinkthc.com/research/RTHC-01308

APA

Wills, Kiri L; Parker, Linda A. (2016). Effect of Pharmacological Modulation of the Endocannabinoid System on Opiate Withdrawal: A Review of the Preclinical Animal Literature.. Frontiers in pharmacology, 7, 187. https://doi.org/10.3389/fphar.2016.00187

MLA

Wills, Kiri L, et al. "Effect of Pharmacological Modulation of the Endocannabinoid System on Opiate Withdrawal: A Review of the Preclinical Animal Literature.." Frontiers in pharmacology, 2016. https://doi.org/10.3389/fphar.2016.00187

RethinkTHC

RethinkTHC Research Database. "Effect of Pharmacological Modulation of the Endocannabinoid ..." RTHC-01308. Retrieved from https://rethinkthc.com/research/wills-2016-effect-of-pharmacological-modulation

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.